Faslodex in McCune-Albright Syndrome
NCT00278915
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
30
Enrollment
INDUSTRY
Sponsor class
Conditions
Puberty, Precocious
McCune-Albright Syndrome
Interventions
DRUG:
Fulvestrant
Sponsor
AstraZeneca